APA (7th ed.) Citation

T, U., K, H., H, N., T, J., H, M., W, F., . . . K, K. (2026). Author's reply to 'Bayesian interpretation of febrile neutropenia risk and primary G-CSF prophylaxis during darolutamide triplet therapy'. Japanese journal of clinical oncology. https://doi.org/10.1093/jjco/hyag059

Chicago Style (17th ed.) Citation

T, Uchimoto, et al. "Author's Reply to 'Bayesian Interpretation of Febrile Neutropenia Risk and Primary G-CSF Prophylaxis During Darolutamide Triplet Therapy'." Japanese Journal of Clinical Oncology 2026. https://doi.org/10.1093/jjco/hyag059.

MLA (9th ed.) Citation

T, Uchimoto, et al. "Author's Reply to 'Bayesian Interpretation of Febrile Neutropenia Risk and Primary G-CSF Prophylaxis During Darolutamide Triplet Therapy'." Japanese Journal of Clinical Oncology, 2026, https://doi.org/10.1093/jjco/hyag059.